West Pharmaceutical Services Inc. ($WST) Stock Forecast: Up 14.1% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services (WST) is a company specializing in the production of components for drug delivery systems, including GLP-1 weight-loss medications. The stock had a strong bullish movement today amidst positive news regarding its Q1 2026 earnings report.

Why is West Pharmaceutical Services Inc. going up?

WST stock is up 14.1% on Apr 23, 2026 18:43

• Impressive Q1 2026 results were reported by West Pharmaceutical Services, with revenues up 21% and adjusted EPS exceeding expectations by 47%, showcasing strong financial performance.
• The company's role in producing components for drug delivery, particularly in the growing weight-loss drug market, has positioned it as a significant player, leading to a surge in its stock price.
• Despite facing near-term challenges like a CGM contract roll-off and rising commodity costs, West Pharmaceutical Services raised its full-year guidance, emphasizing continued margin expansion through favorable product mix and operational efficiencies.
• The market's muted reaction to the positive earnings report suggests that investors may be adopting a wait-and-see approach, potentially awaiting further developments or clarification on the company's outlook despite the strong performance.

WST Price Chart

WST Technical Analysis

WST News

West Pharmaceutical Services Q1 2026 Earnings Call Transcript

West Pharmaceutical Services reported strong Q1 2026 results with revenues up 21% and adjusted EPS up 47%, exceeding expectations. The company raised its full-year guidance, driven by robust performance in HVP components, particularly GLP-1 and biologics, and ongoing Annex I conversions. Despite near-term headwinds like a CGM contract roll-off and rising commodity costs, West expects continued margin expansion due to favorable product mix and operational efficiencies.

https://www.marketbeat.com/earnings/reports/2026-4-23-west-pharmaceutical-services-inc-stock/

West Pharmaceutical Stock Is Soaring After Earnings. It’s a Sneaky GLP-1 Play.

West Pharmaceutical Services (WST) saw its stock soar after its recent earnings report, driven by its role in producing components for drug delivery, including GLP-1 weight-loss medications. While companies like Eli Lilly and Novo Nordisk are well-known for GLP-1s, West Pharmaceutical presents a less obvious, yet significant, investment opportunity in the growing weight-loss drug market.

https://www.barrons.com/articles/west-pharmaceutical-stock-prices-earnings-glp-1-a2c38b25

Air Products and Chemicals stock hits 52-week high at $301.34

Air Products and Chemicals (APD) stock reached a new 52-week high of $301.34, with current trading around $299.93, reflecting a 21.77% year-to-date return. Despite its strong performance and a 2.44% dividend yield maintained for 56 years, InvestingPro analysis indicates the stock may be overvalued. Analysts have upgraded their ratings and increased price targets for the industrial gases company, citing improved capital allocation and stable earnings growth.

https://www.investing.com/news/company-news/air-products-and-chemicals-stock-hits-52week-high-at-30134-93CH-4632886

Cumberland Pharmaceuticals to sell branded drug unit to Apotex for $100M

Cumberland Pharmaceuticals announced an agreement to sell its branded pharmaceutical line to an affiliate of Apotex for $100 million in cash, a deal representing more than twice Cumberland’s current market capitalization. The company will retain its product pipeline and its majority ownership in Cumberland Emerging Technologies Inc. Cumberland is actively developing ifetroban, a thromboxane antagonist, through three separate programs, including one for Duchenne muscular dystrophy with FDA designations.

https://www.investing.com/news/company-news/cumberland-pharmaceuticals-to-sell-branded-drug-unit-to-apotex-for-100m-93CH-4632724

West Pharmaceutical Services Crushes Q1 2026 Profit Estimates by 26.0%

West Pharmaceutical Services (NYSE:WST) significantly surpassed Q1 2026 profit estimates by 26.0%, reporting adjusted earnings of $2.13 per share against a $1.69 consensus. The company also saw robust revenue growth, reaching $844.9 million, a 21.0% increase year-over-year, driven by strong demand in its Proprietary Products segment. Despite the strong financial performance and positive analyst outlook, the stock's market reaction was muted, with shares trading largely unchanged.

https://news.alphastreet.com/west-pharmaceutical-services-crushes-q1-2026-profit-estimates-by-26-0/

Trending Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.6% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.1% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Down 5.5% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 7.2% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 5.0% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.1% Today

Innovative Industrial Properties Inc ($IIPR) Stock Forecast: Up 5.4% Today

Southwest Airlines Company ($LUV) Stock Forecast: Up 5.3% Today

eBay Inc. ($EBAY) Stock Forecast: Down 4.7% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 11.3% Today

West Pharmaceutical Services Inc. Price History

10.02.2026 - WST Stock was down 5.2%

• The bearish movement in WST stock may be linked to uncertainty surrounding an upcoming CEO transition, as Eric Green, credited with significant company growth, prepares to retire.
• Despite strong Q4 2025 earnings and positive 2026 guidance, concerns about the leadership change and its potential effect on future growth may have prompted investor caution.
• Projected growth in the pharmacy blister packaging market presents potential opportunities for WST, but investor focus on internal company dynamics rather than broader industry trends is evident.
• Valuation concerns, including a high P/E ratio relative to industry norms, could be contributing to the downward pressure on WST stock as investors reevaluate the company's future post-Green's retirement announcement.

13.01.2026 - WST Stock was up 5.2%

• The bullish movement in WST stock today can be attributed to the company's robust Q4 2025 results and optimistic 2026 guidance, which exceeded market expectations and showcased strong revenue growth driven by high-value product components, GLP-1 demand, and biologics recovery.
• Despite concerns raised in previous quarters about slipping net profit margins and trailing revenue growth, the company's forecasted profit for 2026 above estimates, fueled by strong demand for drug components, has instilled confidence in investors and contributed to the stock's positive performance.
• The tension between bullish growth narratives and financial challenges seems to have been alleviated by the company's updated outlook, emphasizing organic net sales growth and highlighting the positive impact of underlying demand and product mix on its future financial prospects.
• Overall, WST's stock surge today reflects investor optimism surrounding the company's ability to capitalize on the expanding GLP-1 market, strategic investments in innovation, and the promising outlook for its high-value product components in the healthcare industry.

01.03.2026 - WST Stock was up 1.8%

• West Pharmaceutical Services stock experienced a bullish movement, closing 2.24% higher.
• The expansion of the Dublin facility to support high-volume injectable therapies, particularly for diabetes and obesity, likely contributed to investor optimism.
• Despite underperforming the broader market, the company's strategic initiatives, such as the new facility and strong financial performance, have garnered positive attention from analysts and investors.
• The announcement of a $1 billion share buyback and a "Buy" rating with a consensus target price of $314.56 further boosted investor confidence in West Pharmaceutical Services' growth prospects.

04.01.2026 - WST Stock was up 5.0%

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

23.03.2026 - WST Stock was up 15.5%

• West Pharmaceutical Services (WST) exceeded market expectations for Q1 CY2026, reporting impressive revenue and adjusted EPS figures, which led to a significant surge in the stock price.
• The company's robust performance was attributed to strong market demand and increased production capacity, showcasing its ability to capitalize on current industry trends.
• Analysts and investors reacted positively to the earnings beat and optimistic guidance provided by West Pharmaceutical, driving further confidence in the company's growth trajectory.
• The focus on the company's exposure to key growth drivers like GLP-1 diabetes and obesity treatments, alongside strategic initiatives such as facility expansions and leadership transitions, added complexity and investor interest to the overall bullish sentiment surrounding West Pharmaceutical Services.

23.03.2026 - WST Stock was up 13.4%

• WST exceeded Q1 2026 profit estimates by 26.0% and reported robust revenue growth, fueled by strong demand in its Proprietary Products segment.
• Despite the positive financial results and raised guidance, the market response to the earnings report was somewhat subdued, with shares trading relatively flat.
• Analysts and investors may have already factored in the strong performance, resulting in a limited immediate impact on the stock price despite the impressive earnings beat.
• The general bullish sentiment in the market towards firms with solid financial performance and growth potential could have influenced the positive movement in WST's stock price.

23.03.2026 - WST Stock was up 14.1%

• Impressive Q1 2026 results were reported by West Pharmaceutical Services, with revenues up 21% and adjusted EPS exceeding expectations by 47%, showcasing strong financial performance.
• The company's role in producing components for drug delivery, particularly in the growing weight-loss drug market, has positioned it as a significant player, leading to a surge in its stock price.
• Despite facing near-term challenges like a CGM contract roll-off and rising commodity costs, West Pharmaceutical Services raised its full-year guidance, emphasizing continued margin expansion through favorable product mix and operational efficiencies.
• The market's muted reaction to the positive earnings report suggests that investors may be adopting a wait-and-see approach, potentially awaiting further developments or clarification on the company's outlook despite the strong performance.

12.01.2026 - WST Stock was down 7.5%

• Today, despite reporting strong Q4 2025 earnings and issuing optimistic guidance for FY 2026, West Pharmaceutical Services (WST) saw a bearish movement in its stock. Possible reasons for this unexpected market reaction include:
• The market potentially factoring in the positive earnings beat and revenue results from Q4 2025, leading to profit-taking.
• Analysts expressing concerns about the high valuation of WST stock, with implications raised by TipRanks' AI Analyst, Spark.
• A slight decrease in operating margin, even though the free cash flow margin improved, raising questions about future profitability and efficiency.
• General market conditions or sector-specific factors that overshadowed West Pharmaceutical Services' positive financial performance.

12.01.2026 - WST Stock was down 3.4%

• Despite posting solid Q4 and 2025 results with strong revenue growth and beating earnings estimates, West Pharmaceutical Services (WST) experienced a bearish movement in the stock market.
• The bearish trend could be linked to an AI Analyst assigning a Neutral rating to WST, citing high valuation concerns despite the company's strong financial performance.
• Moreover, investors seemed worried about the planned divestiture of its SmartDose 3.5mL system, raising uncertainties about future revenue streams and prompting a sell-off.
• In conclusion, while the company showcased robust financial performance and positive 2026 outlook, market sentiment and valuation worries likely played a part in the stock's bearish movement.

06.01.2026 - WST Stock was up 5.2%

• Strong bullish movement in the market today for WST.
• Announcement of an integrated syringe system to streamline pharmaceutical development and supply chain management, with positive industry feedback.
• Expectations of earnings growth and higher revenues for the quarter ended December 2025, despite some analysts expressing dissenting views.
• Anticipation of insights into demand trends for injectable therapies and growth projections in the upcoming earnings reveal.
• WST's commitment to driving innovation in cancer treatment packaging, reflecting dedication to advancing healthcare solutions and making an impact in the fight against cancer.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.00.2026 - WST Stock was down 6.9%

• Despite positive developments like the sale of SmartDose rights to AbbVie and a "strong-buy" rating from Zacks Research, WST saw a decline in its market value today.
• The market's negative reaction may be attributed to concerns about the impact of selling a product that contributed significantly to WST's revenue in 2025, leading to uncertainties regarding future earnings.
• While the industry outlook is favorable and growth prospects are promising, investors may be wary of WST's strategic shift and the challenges highlighted in recent reports.
• The extended collaboration between BD and Ypsomed to target the expanding biologics market could intensify competition in the drug delivery systems sector, creating additional pressure on WST's market standing.